<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Powell, Jerry S.</style></author><author><style face="normal" font="default" size="100%">Tiede, Andreas</style></author><author><style face="normal" font="default" size="100%">Sokal, Etienne</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances and Potential in Treatment of Hemophilia A</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-10 10:58:07</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of hemophilia A is benefiting from extended half-life recombinant factor VIII compounds that maintain higher trough levels of drug with less frequent dosing. A variety of pegylated recombinant factor VIII compounds are available. A promising avenue of treatment is the targeted use of liver mesenchymal stem cells that produce factor VIII.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>